

# TAR-210 Erdafitinib Intravesical Delivery System in Non–Muscle-Invasive Bladder Cancer With Select *FGFR* Alterations: Updated First-in-Human Results

**Antoni Vilaseca<sup>1</sup>, Gautam Jayram<sup>2</sup>, Carles Raventos<sup>3</sup>, Neal D Shore<sup>4</sup>, Daniel Zainfeld<sup>5</sup>, Taek Won Kang<sup>6</sup>, Ja Hyeon Ku<sup>7</sup>, Joshua J Meeks<sup>8</sup>, Óscar Rodríguez Faba<sup>9</sup>, Florian Roghmann<sup>10</sup>, Siamak Daneshmand<sup>11</sup>, Neil Beeharry<sup>12</sup>, Carrye R Cost<sup>12</sup>, Anna Kalota<sup>12</sup>, Josh Lauring<sup>12</sup>, Michelle R Peterson<sup>13</sup>, Michelle Quiroz<sup>12</sup>, Nicole L Stone<sup>12</sup>, Wei Zhu<sup>13</sup>, Felix Guerrero-Ramos<sup>14</sup>**

<sup>1</sup>Hospital Clínic de Barcelona, Barcelona, Spain; <sup>2</sup>Urology San Antonio, San Antonio, TX, USA; <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, Spain; <sup>4</sup>Carolina Urologic Research Center, Myrtle Beach, SC, USA; <sup>5</sup>Urology San Antonio, San Antonio, TX, USA; <sup>6</sup>Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, Korea; <sup>7</sup>Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; <sup>8</sup>Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; <sup>9</sup>Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>10</sup>Ruhr-University Bochum, Marien Hospital, Herne, Germany; <sup>11</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA; <sup>12</sup>Janssen Research & Development, Spring House, PA, USA; <sup>13</sup>Janssen Research & Development, Raritan, NJ, USA; <sup>14</sup>University Hospital 12 de Octubre, Madrid, Spain

<https://www.congresshub.com/Oncology/AUA2024/TAR-210/Vilaseca>

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



# Disclosures

---

- A Vilaseca has received consulting/advisory fees from Accord, Astellas, Bayer, and Janssen, and travel support from Astellas, Janssen, and Recordati

This material is distributed for scientific purposes on Janssen Science, and is not for promotional use



# TAR-210 Is Designed to Deliver Sustained Local Delivery of Erdafitinib, a Pan-FGFR Inhibitor, Throughout 3 Months in the Bladder

- Despite available treatment options for patients with NMIBC, recurrence rates remain high, underscoring the need for effective therapies<sup>1</sup>
- Activating *FGFR* alterations are prevalent in 50-80% of patients with NMIBC and may function as oncogenic drivers<sup>2-4</sup>
- Erdafitinib is a selective pan-FGFR tyrosine kinase inhibitor<sup>5</sup>
  - Erdafitinib has regulatory approval in the United States to treat patients with locally advanced or mUC with susceptible *FGFR3* alterations following at least 1 prior systemic treatment, with additional approvals across geographies<sup>6-9</sup>

**TAR-210 is a novel targeted releasing system designed for sustained local delivery of erdafitinib over 3 months in the bladder**



TAR-210 is inserted into the bladder through a dedicated urinary placement catheter and removed via cystoscopy.

FGFR, fibroblast growth factor receptor; mUC, metastatic urothelial carcinoma; NMIBC, non-muscle-invasive bladder cancer.

1. Ritch CR, et al. *J Urol*. 2020;203:505-511. 2. Hernández S, et al. *J Clin Oncol*. 2008;24:3664-3671. 3. Knowles MA, Hurst CD. *Nat Rev Cancer*. 2014;15:25-41. 4. Khalid S, et al. *Eur Urol Open Sci*. 2020;21:61-68. 5. Perera TPS, et al. *Mol Cancer Ther*. 2017;16:1010-1020. 6. BALVERSA® (erdafitinib) [package insert]. Horsham, PA: Janssen Products, LP; 2024. 7. Loriot Y, et al. *N Engl J Med*. 2019;381:338-348. 8. Siefker-Radtke AO, et al. *Lancet Oncol*. 2022;23:248-258. 9. Loriot Y, et al. *N Engl J Med*. 2023;21:1961-1971.



# TAR-210 First-in-Human Phase 1: Cohorts 1 and 3

## Study Design

NCT05316155

### Molecular Eligibility

*FGFR* alterations:

- Flexible molecular eligibility strategy used
  - Local or central fresh/archival **tissue-based** testing by NGS or PCR
  - or—
  - Central **urine cell-free DNA** NGS testing

### HR NMIBC (Cohort 1)

- Recurrent, high-grade Ta/T1, papillary only, no CIS
- BCG-experienced and not undergoing radical cystectomy
- TURBT with complete resection of all visible disease prior to treatment

### IR NMIBC (Cohort 3)

- Recurrent, history of low-grade only Ta/T1 disease
- **Visible target lesions** prior to treatment (chemoablation design)

### Part 1: Dose Escalation

BOIN<sup>1,2</sup>

**TAR-210-B**  
~2 mg/day

**TAR-210-D**  
~4 mg/day

- Placement every 3 months

### Part 2: Dose Expansion

- Expansion of both dose levels

Response assessed every 3 months with continued treatment for up to 1 year if recurrence free (Cohort 1) or complete response (Cohort 3).

Clinical cutoff date: **March 22, 2024.**

BCG, bacillus Calmette-Guérin; BOIN, Bayesian optimization interval; CIS, carcinoma in situ; HR, high risk; IR, intermediate risk; NGS, next-generation sequencing; PCR, polymerase chain reaction; PK, pharmacokinetics; TURBT, transurethral resection of bladder tumor.

1. Liu S, Yuan Y. *J R Stat Soc Ser C Appl Stat.* 2015;64:507-523. 2. Yuan Y, et al. *Clin Cancer Res.* 2016;22:4291-4301.

Presented by A Vilaseca at the 119th AUA Annual Meeting; May 3-6, 2024; San Antonio, TX, USA



# TAR-210 First-in-Human Phase 1: Patient Characteristics

Characteristic	Cohort 1 HR NMIBC (N=21)	Cohort 3 IR NMIBC (N=43)
Age, years, median (range)	73 (62-90)	67 (41-89)
Gender, male, %	71	79
Race, %		
White	81	60
Asian	19	40
ECOG performance status, %		
0	62	79
1	24	14
2	14	7

Characteristic	Cohort 1 HR NMIBC (N=21)	Cohort 3 IR NMIBC (N=43)
Tumor stage, %		
Ta	76	95 <sup>a</sup>
T1	24	5 <sup>a</sup>
Multiple tumors, %	43	43 <sup>a</sup>
Prior BCG, %	100	21
Prior intravesical chemotherapy, %	10	51
Prior TURBT and tumor ablation procedures, median (range) <sup>b</sup>	4 (1-12)	2 (1-14)
<i>FGFR</i> alterations, %		
<i>FGFR3</i> mutations	90	95
<i>FGFR3</i> gene fusions	10	5


ECOG, Eastern Cooperative Oncology Group.

<sup>a</sup>N=42. <sup>b</sup>Prior cancer-related surgery/procedure of interest were counted only once on a given date and includes the following procedures: fulguration, cauterization, and laser photocoagulation.



# TAR-210 HR NMIBC (Cohort 1): Results

## HR NMIBC With *FGFR* Alterations (Cohort 1) (N=21)



- **90% estimated 12-month RFS rate<sup>a</sup>** (n=21)
  - Median RFS was not estimable
  - 2 of 21 patients have recurred
  - Median duration of follow-up 8.9 months
- No difference observed in RFS between the TAR-210 dose levels


+ Indicates patient was censored; CI, confidence interval; CR, complete response; NE, non-estimable; RFS, recurrence-free survival.

<sup>a</sup>All treated patients were efficacy evaluable. RFS was estimated using the Kaplan-Meier method.



# TAR-210 IR NMIBC (Cohort 3): Results

## IR NMIBC With *FGFR* Alterations (Cohort 3) (N=43)<sup>a</sup>



- Overall, 31 patients were evaluable for response<sup>b</sup>
- 90% CR rate**, with 28/31 patients achieving a CR at Week 12
- Overall, **100% of patients achieved a clinical response**; 3 patients had a non-CR/non-PD response
- Consistent CR rate across both doses
- 86% (24/28) of CRs are ongoing at time of clinical cutoff


Durable response rate at specific landmarks <sup>c</sup>	% (95% CI)
6 months	100 (100-100)
9 months	89 (43-98)

+ Indicates patient was censored; DOR, duration of response; PD, progressive disease.

<sup>a</sup>43 patients were treated; 31 patients were efficacy evaluable for CR and DOR. <sup>b</sup>Efficacy evaluable patients were those having at least one disease evaluation or discontinuing treatment prior to their first disease evaluation for either PD or recurrence. <sup>c</sup>DOR was estimated using the Kaplan-Meier method.



# TAR-210 Provided Sustained Erdafitinib Concentrations in Urine With Very Low Plasma Concentrations



- No hyperphosphatemia was reported, consistent with the very low plasma concentrations observed with TAR-210
- Mean plasma erdafitinib concentrations were  $>50\times$  lower than mean urine concentrations





# Safety and Tolerability of TAR-210 in HR NMIBC (Cohort 1) and IR NMIBC (Cohort 3)

- The majority of AEs were grade 1/2 lower urinary tract AEs
- Few patients discontinued due to AEs
  - 2 patients (3%) discontinued due to TRAEs of low-grade urinary symptoms
- 2 patients had serious TRAEs with pyelonephritis and sepsis or UTI and sepsis, respectively
  - Both events resolved with antibiotics and patients were able to continue TAR-210
- No dose-limiting toxicities were identified

Patients with events, n (%)	HR NMIBC (Cohort 1)		IR NMIBC (Cohort 3)		All patients (N=64)
	TAR-210-B ~2 mg/day (n=10)	TAR-210-D ~4 mg/day (n=11)	TAR-210-B ~2 mg/day (n=21)	TAR-210-D ~4 mg/day (n=22)	
≥1 AE	10 (100)	9 (82)	20 (95)	15 (68)	54 (84)
≥1 TRAE <sup>a</sup>	9 (90)	5 (55)	9 (43)	6 (27)	30 (47)
Hematuria	5 (50)	2 (18)	7 (33)	4 (18)	18 (28)
Dysuria	4 (40)	2 (18)	4 (19)	2 (9)	12 (19)
Micturition urgency	2 (20)	1 (9)	5 (24)	0	8 (13)
UTI	0	1 (9)	3 (14)	1 (5)	5 (8)
Urethral pain	1 (10)	1 (9)	1 (5)	0	3 (5)
Cystitis noninfective	0	0	1 (5)	1 (5)	2 (3)
≥1 TRAE of grade ≥2	3 (30)	3 (27)	6 (29)	2 (9)	14 (22)

AE, adverse event; TRAE, treatment-related adverse event; UTI, urinary tract infection.

<sup>a</sup>Listed are AEs related to TAR-210 by preferred term that were reported in >1 patient in either cohort.



# Conclusions: First-in-Human TAR-210 in HR and IR NMIBC

- TAR-210 shows **promising clinical activity** in patients with *FGFR*-altered HR and IR NMIBC
  - In BCG-experienced HR NMIBC (Cohort 1), estimated 12-month RFS rate was **90% (95% CI, 66-97)**
    - With 2 recurrence events and a median follow-up of 8.9 months, the median RFS was not reached
  - In IR NMIBC (Cohort 3), **90% (95% CI, 74-98)** of patients achieved a CR at Week 12
    - 86% of CRs are ongoing at time of clinical cutoff
- TAR-210 provided high erdafitinib concentrations in urine with very low plasma concentrations, **limiting systemic toxicities**
  - Oral erdafitinib-associated eye and skin toxicities and hyperphosphatemia were not observed
- **The majority of TRAEs were grade 1 or 2** lower urinary tract AEs, with low rates of treatment discontinuation (3%) due to TRAEs

**Based on these first-in-human results, the phase 3 MoonRISe-1 study in *FGFR*-altered intermediate-risk NMIBC has been initiated**  
(Li R, et al. *Presented in the Learning Lab this morning*)



# Acknowledgments

<https://www.congresshub.com/Oncology/AUA2024/TAR-210/Vilaseca>

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



- We thank the patients who participated in the study, their families, and the investigators and clinical research staff from the study centers
- This study was sponsored by Janssen Research & Development LLC, a Johnson & Johnson company
- Erdafitinib was discovered in collaboration with Astex Pharmaceuticals
- Editorial support was provided by Nicolisha Narainpersad, PhD, of Parexel and funded by Janssen Global Services, LLC